Last updated on June 2018

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy


Brief description of study

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Clinical Study Identifier: NCT03024996

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: WO39210 ...

Urology Associates of Kingsport, P.C.
Kingsport, TN United States
4.51miles
  Connect »